Teva and Eisai to Co-Develop Drug for Alzheimer's

A long-term strategic alliance for the development of rasagiline for Alzheimer's and other diseases has been announced by Teva Pharmaceutical Industries Ltd. (Jerusalem, Israel) and Eisai Co., Ltd. (Tokyo, Japan). The two companies will also co-promote the drug for Parkinson's disease following approval by the US Food and Drug Administration (FDA).

Rasagiline, developed by Teva and the Technion Research and Development Foundation (Haifa, Israel), is a selective and potent irreversible monoamine oxidase type B (MAO-B) inhibitor agent. Phase III clinical trials involving more than 1,500 patients with Parkinson's disease who took the compound showed statistically significant results.

"We are very pleased to partner with Eisai, a world leader in the field of Alzheimer's,” said Israel Makov, president and CEO of Teva. "This agreement is consistent with our strategy to align ourselves with partners, sharing with them the challenges and the opportunities of our innovative pipeline.”

Teva develops, manufactures, and markets generic and innovative human pharmaceuticals. The company's research and development are focused on developing novel drugs for diseases of the central nervous system. Eisai is a research-based healthcare company that discovers, develops, and markets products in more than 30 countries.





Related Links:
Teva
Eisai